At a glance
ClinicalIndex Comparison Record- ✓Histologically confirmed, newly diagnosed high-grade glioma: anaplastic astrocytoma, glioblastoma multiforme, or gliosarcoma
- ✓Primary spinal cord malignant gliomas are allowed
- ✓Surgical resection or biopsy of tumor within past 31 days
- ✓Pre-operative and post-operative brain MRI with and without gadolinium-contrast (or spine MRI for spinal cord primaries)
- ✕Primary brainstem tumors
- ✕Hypersensitivity to temozolomide
- ✕Prior biologic agents or chemotherapy
- ✕Concurrent corticosteroids as antiemetic (allowed only for increased intracranial pressure)
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of Concurrent Radiation and Temozolomide Followed By Temozolomide and CCNU in the Treatment of Children With High-Grade Glioma
In Brief
A Phase 2 clinical trial evaluating Laboratory Biomarker Analysis, Lomustine, and 2 other interventions for Anaplastic Astrocytoma and 4 related conditions. Completed, enrolled 118 participants across 1 site.
Detailed Summary
This phase II trial is studying how well giving radiation therapy together with temozolomide and lomustine works in treating young patients with newly diagnosed gliomas. Radiation therapy uses high energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as temozolomide and lomustine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving radiation therapy together with temozolomide and lomustine after surgery may kill any remaining tumor cells.
Study Details
Timeline
Interventions
Correlative studies
Given PO
Undergo radiation therapy
Given PO